Pfizer 2011 Annual Review | Pfizer: the world's largest research-based pharmaceutical company

Diversified Businesses

Pfizer's Diversified Businesses are responsible for meeting and anticipating customer needs with innovative, meaningful products that advance health and well-being.


    Pfizer Consumer Healthcare is one of the largest over-the-counter (OTC) health care product businesses in the world. Millions of people rely on our products to live healthier lives—using them to relieve pain, control coughs and balance nutrition, among other needs. Many of our well-known products have reached international status, and Advil and Centrum rank among the global Top Ten, a testament to the success of our science-based solutions.

    2011 Highlights

    • Launched 25 consumer health care products in more than 15 countries—more than twice the number of launches over the previous year. Many represented category "firsts," including the Canadian debut of Advil Nighttime, the first sleep aid of this type approved for OTC use in that market. The year also marked the U.S. launch of the ProNutrients brand (Omega-3s, Probiotics and Fruit & Veggie), Centrum Specialist, and Caltrate Gummy Bites, among others. International key launches included Caltrate Plus in China, Caltrate Plus Glucosamine in Taiwan and Centrum Cardio in 13 countries across Europe.

    • Expanded into strategic new markets and product categories by acquiring Ferrosan's consumer health business. Ferrosan expanded our global portfolio to include leading brands within multivitamins and minerals, probiotics, omega-3s and more, such as IMEDEEN, whose proven formulas work deep in the dermal layer, where traditional skin therapies cannot reach.

    • Adapted our research and development organization to meet the needs of consumers in high-growth markets by opening a new R&D center in Suzhou, China.

    • Drove Advil to become the No.1 brand in its category in North America—and the No. 1 selling OTC analgesic brand in the world.


    Our Nutrition Unit's portfolio includes a full line of infant formulas, follow-on formulas, growing-up milks, and prenatal and adult supplements. Safety and quality are our highest priorities. We market our infant formulas in accordance with the principles of the World Health Organization Code of Marketing of Breast Milk Substitutes. We meet or exceed all food quality and safety standards set by the Codex Alimentarius Commission, and comply with all regulations in the countries where we operate.

    2011 Highlights

    • Announced exploration of strategic alternatives for the business; options may include a full or partial separation from Pfizer through a spin-off, sale or other transaction.

    • Launched 32 new products, including the reformulated Gold line, illuma, Picky Eater, Specials, Bonna and Enercal Plus.


    A world leader in the discovery, development, and manufacture of innovative animal vaccines, medicines and diagnostics, we are working to help ensure a safe, sustainable global food supply from healthy beef and dairy cattle, pigs, poultry and fish—while helping companion animals and horses live longer, healthier lives.

    Our portfolio includes many of the world's leading veterinary brands in pharmaceuticals and biologicals, complemented by innovative immunodiagnostic products and a range of animal health services for veterinarians.

    2011 Highlights

    • Announced exploration of strategic alternatives for the business; options may include a full or partial separation from Pfizer through a spin-off, sale or other transaction.

    • Entered into a joint venture with Jilin Guoyuan Animal Health Company Ltd. to develop, manufacture and distribute animal vaccines in China, the world's second-largest animal health market.

    • Integrated the Alpharma LLC animal health subsidiary of the King Pharmaceuticals acquisition. Alpharma's portfolio of medicated feed additives, water-soluble therapeutics, and probiotics complemented Pfizer's portfolio and brought nutrition expertise.

    • Received $10 million innovation grant from The Netherlands Ministry of Economic Affairs, Agriculture and Innovation to develop novel anti-infective veterinary medicines with potential use in food production animals. Pfizer was the only commercial partner selected for this project and has exclusive global rights to any new products or intellectual property arising from this research.

    • Received U.S. and Canadian approvals for Fostera PCV, a vaccine that protects against porcine circovirus, the most common illness in pigs.

    • Received U.S. and Canadian approvals for Improvest (known as Improvac in other markets), a novel immunologic product for swine.

    • Became the founding animal health industry member of the Global Strategic Alliances for the Coordination of Research on the Major Infectious Diseases of Animals and Zoonoses, which is funded by the European Commission and coordinated by the U.K.'s Department for Environment, Food and Rural Affairs. This alliance brings together thousands of scientists from research and regulatory organizations across
      five continents.